Tumor Biology

, Volume 36, Issue 5, pp 3407–3415 | Cite as

Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2

  • Chien-Min Chen
  • Yi-Hsien Hsieh
  • Jin-Ming Hwang
  • Hsun-Jin Jan
  • Shu-Ching Hsieh
  • Shin-Huey Lin
  • Chung-Yu Lai
Research Article

Abstract

Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a naturally occurring flavonoid which is widely distributed in plants. It has been reported to possess some anticancer and anti-invasive capabilities. We set out to explore the effects of fisetin on antimetastatic and its mechanism of action in GBM8401 cells. The results indicated that fisetin exhibited effective inhibition of cell migration and inhibited the invasion of GBM8401 cells under non-cytotoxic concentrations. To identify the potential targets of fisetin, human proteinase antibody array analysis was performed, and the results indicated that the fisetin treatment inhibited the expression of ADAM9 protein and mRNA, which are known to contribute to the progression of glioma cancer. Our results showed that fisetin phosphorylated ERK1/2 in a sustained way that contributed to the inhibited ADAM9 protein and mRNA expression determined by Western blot and RT-PCR. Moreover, inhibition of ERK1/2 by U0126 or transfection with the siERK plasmid significantly abolished the fisetin-inhibited migration and invasion through activation of the ERK1/2 pathway. In summary, our results suggest that fisetin might be a potential therapeutic agent against human glioma cells based on its capacity to activate ERK1/2 and to inhibit ADAM9 expression.

Keywords

Glioma cancer cells Fisetin Migration Invasion ADAM9 

Notes

Acknowledgments

This work was supported by grants from Chung Shan Medical University (CSMU-INT-102-15) and Chung Shan Medical University and Changhua Christian Hospital, Changhua, Taiwan (CSMU-CCH-103-02).

Conflicts of interest

None

References

  1. 1.
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Song PM, Zhang Y, He YF, Bao HM, Luo JH, et al. Bioinformatics analysis of metastasis-related proteins in hepatocellular carcinoma. World J Gastroenterol. 2008;14:5816–22.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Tan W, Lu J, Huang M, Li Y, Chen M, et al. Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med. 2011;6:27.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Meiyanto E, Hermawan A, Anindyajati. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev. 2012;13:427–36.CrossRefPubMedGoogle Scholar
  5. 5.
    Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat. 1993;24:209–18.CrossRefPubMedGoogle Scholar
  6. 6.
    Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem. 2004;279:33168–76.CrossRefPubMedGoogle Scholar
  7. 7.
    Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer. 2003;106:372–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Kemik O, Kemik AS, Sumer A, Dulger AC, Adas M, et al. Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer. World J Gastroenterol. 2011;17:2109–12.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, et al. The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer. 2012;12:583.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Behrens P, Rothe M, Florin A, Wellmann A, Wernert N. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med. 2001;8:149–54.PubMedGoogle Scholar
  11. 11.
    Fang S, Jin X, Wang R, Li Y, Guo W, et al. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis. 2005;26:481–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Petrella BL, Armstrong DA, Vincenti MP. CCAAT-enhancer-binding protein beta activation of MMP-1 gene expression in SW1353 cells: independent roles of extracellular signal-regulated and p90/ribosomal S6 kinases. J Cell Physiol. 2011;226:3349–54.CrossRefPubMedGoogle Scholar
  13. 13.
    Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000;6:4823–30.PubMedGoogle Scholar
  14. 14.
    Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999;98:137–46.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Husmann K, Arlt MJ, Muff R, Langsam B, Bertz J, et al. Matrix metalloproteinase-1 promotes tumor formation and lung metastasis in an intratibial injection osteosarcoma mouse model. Biochim Biophys Acta. 1832;2013:347–54.Google Scholar
  16. 16.
    Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima MF, et al. Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer. 2012;12:121.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Isbrucker RA, Burdock GA. Risk and safety assessment on the consumption of licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol. 2006;46:167–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Jiang J, Yuan X, Zhao H, Yan X, Sun X, et al. Licochalcone A inhibiting proliferation of bladder cancer T24 cells by inducing reactive oxygen species production. Biomed Mater Eng. 2014;24:1019–25.PubMedGoogle Scholar
  19. 19.
    Chu X, Ci X, Wei M, Yang X, Cao Q, et al. Licochalcone A inhibits lipopolysaccharide-induced inflammatory response in vitro and in vivo. J Agric Food Chem. 2012;60:3947–54.CrossRefPubMedGoogle Scholar
  20. 20.
    Xiao XY, Hao M, Yang XY, Ba Q, Li M, et al. Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis. Cancer Lett. 2011;302:69–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Kim YH, Shin EK, Kim DH, Lee HH, Park JH, et al. Antiangiogenic effect of licochalcone A. Biochem Pharmacol. 2010;80:1152–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Tsai JP, Hsiao PC, Yang SF, Hsieh SC, Bau DT, et al. Licochalcone A suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-kappaB-mediated urokinase plasminogen activator expression. PLoS One. 2014;9:e86537.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Green JA, Elkington PT, Pennington CJ, Roncaroli F, Dholakia S, et al. Mycobacterium tuberculosis upregulates microglial matrix metalloproteinase-1 and -3 expression and secretion via NF-kappaB- and activator protein-1-dependent monocyte networks. J Immunol. 2010;184:6492–503.CrossRefPubMedGoogle Scholar
  24. 24.
    Lee YR, Noh EM, Han JH, Kim JM, Hwang JK, et al. Brazilin inhibits UVB-induced MMP-1/3 expressions and secretions by suppressing the NF-kappaB pathway in human dermal fibroblasts. Eur J Pharmacol. 2012;674:80–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Ferrari MM, Rossi G, Biondi ML, Vigano P, Dell’utri C, et al. Type I collagen and matrix metalloproteinase 1, 3 and 9 gene polymorphisms in the predisposition to pelvic organ prolapse. Arch Gynecol Obstet. 2012;285:1581–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010;67:257–74.CrossRefPubMedGoogle Scholar
  27. 27.
    Pandey M, Mathew A, Nair MK. Global perspective of tobacco habits and lung cancer: a lesson for third world countries. Eur J Cancer Prev. 1999;8:271–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.CrossRefPubMedGoogle Scholar
  29. 29.
    Sarkar FH, Li YW. Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol Sin. 2007;28:1305–15.CrossRefPubMedGoogle Scholar
  30. 30.
    Weng CJ, Yen GC. Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev. 2012;38:76–87.CrossRefPubMedGoogle Scholar
  31. 31.
    Chetty C, Rao JS, Lakka SS. Matrix metalloproteinase pharmacogenomics in non-small cell lung carcinoma. Pharmacogenomics. 2011;12:535–46.CrossRefPubMedGoogle Scholar
  32. 32.
    Lopez-Otin C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle. 2009;8:3657–62.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Li M, Xiao T, Zhang Y, Feng L, Lin D, et al. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer. 2010;69:341–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Jung JS, Ahn JH, Le TK, Kim DH, Kim HS. Protopanaxatriol ginsenoside Rh1 inhibits the expression of matrix metalloproteinases and the in vitro invasion/migration of human astroglioma cells. Neurochem Int. 2013;63:80–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Lee EJ, Kim SY, Hyun JW, Min SW, Kim DH, et al. Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. Chem Biol Interact. 2010;185:18–24.CrossRefPubMedGoogle Scholar
  36. 36.
    Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802;2010:396–405.Google Scholar
  37. 37.
    Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–49.CrossRefPubMedGoogle Scholar
  38. 38.
    Besson A, Davy A, Robbins SM, Yong VW. Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene. 2001;20:7398–407.CrossRefPubMedGoogle Scholar
  39. 39.
    Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, et al. Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer. 2010;10:593.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Zhang Z, Lv J, Lei X, Li S, Zhang Y, et al. Baicalein reduces the invasion of glioma cells via reducing the activity of p38 signaling pathway. PLoS One. 2014;9:e90318.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Zhou X, Hua L, Zhang W, Zhu M, Shi Q, et al. FRK controls migration and invasion of human glioma cells by regulating JNK/c-Jun signaling. J Neurooncol. 2012;110:9–19.CrossRefPubMedGoogle Scholar
  42. 42.
    Chen YY, Liu FC, Chou PY, Chien YC, Chang WS, et al. Ethanol extracts of fruiting bodies of Antrodia cinnamomea suppress CL1-5 human lung adenocarcinoma cells migration by inhibiting matrix metalloproteinase-2/9 through ERK, JNK, p38, and PI3K/Akt signaling pathways. Evid Based Complement Alternat Med. 2012;378415Google Scholar
  43. 43.
    Radziwon-Balicka A, Santos-Martinez MJ, Corbalan JJ, O’Sullivan S, Treumann A, et al. Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway. Carcinogenesis. 2014;35:324–32.CrossRefPubMedGoogle Scholar
  44. 44.
    Faust D, Schmitt C, Oesch F, Oesch-Bartlomowicz B, Schreck I, et al. Differential p38-dependent signalling in response to cellular stress and mitogenic stimulation in fibroblasts. Cell Commun Signal. 2012;10:6.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988–1004.CrossRefPubMedGoogle Scholar
  46. 46.
    Yoon SO, Shin S, Lee HJ, Chun HK, Chung AS. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol Cancer Ther. 2006;5:2666–75.CrossRefPubMedGoogle Scholar
  47. 47.
    Veit C, Genze F, Menke A, Hoeffert S, Gress TM, et al. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res. 2004;1–5300.Google Scholar
  48. 48.
    Gunther W, Skaftnesmo KO, Arnold H, Terzis AJ. Molecular approaches to brain tumour invasion. Acta Neurochir (Wien). 2003;145:1029–36.CrossRefGoogle Scholar
  49. 49.
    Hanai J, Doro N, Sasaki AT, Kobayashi S, Cantley LC, et al. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol. 2012;227:1709–20.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Lin YC, Lin JC, Hung CM, Chen Y, Liu LC, et al. Osthole inhibits insulin-like growth factor-1-induced epithelial to mesenchymal transition via the inhibition of PI3K/Akt signaling pathway in human brain cancer cells. J Agric Food Chem. 2014;62:5061–71.CrossRefPubMedGoogle Scholar
  51. 51.
    Li Z, Du L, Li C, Wu W. Human chorionic gonadotropin beta induces cell motility via ERK1/2 and MMP-2 activation in human glioblastoma U87MG cells. J Neurooncol. 2013;111:237–44.CrossRefPubMedGoogle Scholar
  52. 52.
    Li Z, Li C, Du L, Zhou Y, Wu W. Human chorionic gonadotropin beta induces migration and invasion via activating ERK1/2 and MMP-2 in human prostate cancer DU145 cells. PLoS One. 2013;8:e54592.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Li C, Zhou Y, Peng X, Du L, Tian H, et al. Sulforaphane inhibits invasion via activating ERK1/2 signaling in human glioblastoma U87MG and U373MG cells. PLoS One. 2014;9:e90520.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Chien-Min Chen
    • 1
  • Yi-Hsien Hsieh
    • 2
  • Jin-Ming Hwang
    • 3
  • Hsun-Jin Jan
    • 4
  • Shu-Ching Hsieh
    • 5
  • Shin-Huey Lin
    • 6
  • Chung-Yu Lai
    • 7
  1. 1.Division of Neurosurgery, Department of SurgeryChanghua Christian HospitalChanghuaTaiwan
  2. 2.Department of Biochemistry, School of MedicineChung Shan Medical UniversityTaichungTaiwan
  3. 3.Department of Applied Chemistry, School of Medicine, College of MedicineChung Shan Medical UniversityTaichungTaiwan
  4. 4.Graduate Institute of Pharmaceutical Science and TechnologyCentral Taiwan University of Science and TechnologyTaichungTaiwan
  5. 5.Institute of MedicineChung Shan Medical UniversityTaichungTaiwan
  6. 6.Institute of Biochemistry and Biotechnology, College of MedicineChung Shan Medical UniversityTaichungTaiwan
  7. 7.Department of Surgery, Chung-Kang BranchCheng-Ching General HospitalTaichungTaiwan

Personalised recommendations